29.09.2015 • News

Sanofi and Lilly Settle Lantus Patent Row

France’s Sanofi and US drugmaker Eli Lilly have resolved their patent dispute over insulin drugs.

The settlement announced this week ends a US lawsuit brought by the French producer of Lantus SoloSTAR (insulin glargine) in response to its US rival’s pursuit of regulatory approval for a competitive product. The two companies also agreed to discontinue similar disputes worldwide.

As part of the agreement, Lilly will pay royalties to Sanofi in exchange for a license to certain Sanofi patents and will not sell its insulin glargine product on the US market before Dec.15, 2016. The agreement does not extend to Lantus (vial), Toujeo or combination products.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Book

Innovation Management in Sustainable Chemistry

Innovation Management in Sustainable Chemistry

Comprehensive resource on sustainable chemistry, bridging the skill gap between academic science education and innovation and entrepreneurship

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.